Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial sector : Professional, scientific, and technical services save search
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.49 -2.39% -2.45% 110K
|
Professional, Scientific, and T...
|
| O: 0.11%
H: 5.95%
C: -13.78%
mc138 fda ttx-mc138 tumors clearance trial therapeutics advanced
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K
|
Professional, Scientific, and T...
|
| O: -1.5%
H: 0.0%
C: -2.29%
brtx-100 disease trial
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Published: 2024-03-27 (Crawled : 13:30) - globenewswire.com
AVTE M | $21.86 1.2% 1.19% 220K
|
Professional, Scientific, and T...
|
| O: 6.78%
H: 7.19%
C: 4.05%
conference international trial therapeutics
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: -6.67%
H: 10.71%
C: 8.57%
trial therapeutics
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.22%
H: 3.45%
C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
Published: 2024-02-22 (Crawled : 12:30) - prnewswire.com
ELEV | $3.79 -5.49% -5.8% 990K
|
Professional, Scientific, and T...
|
| O: -1.44%
H: 5.49%
C: -1.1%
eo-3021 first japan ongoing trial
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
BIXT A | $0.1285 490.75% 32K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.09%
C: -5.9%
covid-19 drug antiviral trial
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Published: 2024-01-29 (Crawled : 12:00) - prnewswire.com
ACXP | $2.02 -5.16% -5.45% 94K
|
Professional, Scientific, and T...
|
| O: 0.26%
H: 1.55%
C: -5.15%
cure positive ibezapolstat trial
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 -6.31% 66K
|
Professional, Scientific, and T...
|
| O: 2.47%
H: 0.94%
C: -13.1%
momentum pancreatic aspire trial
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
VERA | $37.96 -3.85% -4.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 30.79%
H: 19.79%
C: 13.7%
nephropathy origin positive trial therapeutics
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Published: 2024-01-18 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 -6.31% 66K
|
Professional, Scientific, and T...
|
| O: -5.49%
H: 0.0%
C: -18.9%
publication trial therapy study
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Published: 2024-01-17 (Crawled : 12:00) - prnewswire.com
ACXP | $2.02 -5.16% -5.45% 94K
|
Professional, Scientific, and T...
|
| O: -24.21%
H: 25.83%
C: 25.56%
positive ibezapolstat trial
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
Published: 2024-01-12 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.49 -2.39% -2.45% 110K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
ceo therapeutics
ROSEN, NATIONAL TRIAL LAWYERS, Encourages The Beauty Health Company Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SKIN
Published: 2023-12-25 (Crawled : 20:00) - prnewswire.com
BCLYF | News | $2.28 -10.14% 610
|
Finance
|
| O: 4.35%
H: 0.0%
C: 0.0%
SKIN | $3.25 -5.25% -5.54% 1.2M
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.61%
C: -1.52%
BCS | News | $9.35 1.19% 0.0% 16M
|
Finance
|
| O: -0.13%
H: 1.78%
C: 1.4%
SPWR | $2.215 -1.99% -2.03% 6.3M
|
Producer Manufacturing
|
| O: 0.9%
H: 8.67%
C: 6.44%
company health deadline beauty skin trial
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 3.09%
H: 5.08%
C: 0.0%
first disease kidney dialysis trial therapeutics
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Published: 2023-12-11 (Crawled : 21:00) - globenewswire.com
CNTB | $1.49 -1.97% -2.01% 32K
|
Professional, Scientific, and T...
|
| O: -8.59%
H: 5.75%
C: -0.57%
biopharma global trial
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
Published: 2023-12-11 (Crawled : 15:30) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -1.87%
H: 0.0%
C: -4.76%
al001 fda drug lithium trial
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
MOLN | News | $3.74 -3.54% 6.2K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
mp0533 first positive ongoing aml meeting trial molecular
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
IPSC | $3.06 2.86% 2.78% 110K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
cnty-101 trial therapeutics potential
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes
Published: 2023-12-08 (Crawled : 15:30) - biospace.com/
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 3.59%
H: 10.15%
C: 8.48%
alent-111 control treatment ongoing bmf-219 diabetes study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.